Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1

Esophagus

Volumn 16, Issue 1, 2019, Pages 1-24

  Kitagawa, Yuko ^a   Uno, Takashi ^b   Oyama, Tsuneo ^c   Kato, Ken ^d   Kato, Hiroyuki ^e   Kawakubo, Hirofumi ^a   Kawamura, Osamu ^f   Kusano, Motoyasu ^f   Kuwano, Hiroyuki ^g   Takeuchi, Hiroya ^h   Toh, Yasushi ⁱ   Doki, Yuichiro ^j   Naomoto, Yoshio ^k   Nemoto, Kenji ^l   Booka, Eisuke ^a   Matsubara, Hisahiro ^b   Miyazaki, Tatsuya ^g   Muto, Manabu ^m   Yanagisawa, Akio ⁿ   Yoshida, Masahiro ^o  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Nagano Prefectural Federation of Agricultural Cooperative for Health and Welfare   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

^e FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^f GUNMA UNIVERSITY HOSPITAL   (Japan)

^g GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ NATIONAL KYUSHU CANCER CENTER   (Japan)

^j OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^k KAWASAKI MEDICAL SCHOOL   (Japan)

^l YAMAGATA UNIVERSITY   (Japan)

^m KYOTO UNIVERSITY HOSPITAL   (Japan)

ⁿ KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^o INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

more..

Author keywords

Cancer; Esophagus; Practice guidelines

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER CONTROL; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RISK; CANCER STAGING; CANCER SURGERY; CHEMORADIOTHERAPY; ENDOSCOPIC SURGERY; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; ESOPHAGUS OBSTRUCTION; ESOPHAGUS RESECTION; ESOPHAGUS STENOSIS; HUMAN; JAPAN; MEDICAL SOCIETY; MINIMAL RESIDUAL DISEASE; MORTALITY RATE; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PREOPERATIVE CHEMOTHERAPY; PRIORITY JOURNAL; RISK FACTOR; SUPERFICIAL CANCER; SYSTEMATIC REVIEW; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; TUMOR INVASION; ALGORITHM; ESOPHAGOSCOPY; ESOPHAGUS TUMOR; INCIDENCE; PATHOLOGY;

ALGORITHMS; ESOPHAGEAL NEOPLASMS; ESOPHAGEAL STENOSIS; ESOPHAGOSCOPY; HUMANS; INCIDENCE; JAPAN; NEOPLASM INVASIVENESS; NEOPLASM STAGING; POSTOPERATIVE COMPLICATIONS; RISK FACTORS;

EID: 85052786646     PISSN: 16129059     EISSN: 16129067     Source Type: Journal    
DOI: 10.1007/s10388-018-0641-9     Document Type: Article

References (98)

1. Tachimori Y, Ozawa S, Numasaki H, et al. Comprehensive registry of esophageal cancer in Japan, 2008. Esophagus. 2015;12:130–57.
2. Steevens J, Schouten LJ, Goldbohm RA, et al. Alcohol consumption, cigarette smoking and risk of subtypes of oesophageal and gastric cancer: a prospective cohort study. Gut. 2010;59:39–48.
3. Sakata K, Hoshiyama Y, Morioka S, et al. JACC Study Group, Smoking, alcohol drinking and esophageal cancer: findings from the JACC Study. J Epidemiol. 2005;15(Suppl 2):S212–9.
4. Ishiguro S, Sasazuki S, Inoue M, JPHC Study Group, et al. Effect of alcohol consumption, cigarette smoking and flushing response on esophageal cancer risk: a population-based cohort study (JPHC study). Cancer Lett. 2009;275:240–6.
5. Secretan B, Straif K, Baan R, et al. WHO International Agency for Research on Cancer Monograph Working Group: a review of human carcinogens—part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol. 2009;10:1033–4.
6. Freedman ND, Park Y, Subar AF, et al. Fruit and vegetable intake and esophageal cancer in a large prospective cohort study. Int J Cancer. 2007;121:2753–60.
7. Lagiou P, Talamini R, Samoli E, et al. Diet and upper–aerodigestive tract cancer in Europe: the ARCAGE study. Int J Cancer. 2009;124:2671–6.
8. Yousef F, Cardwell C, Cantwell MM, et al. The incidence of esophageal cancer and high-grade dysplasia in Barrett’ s esophagus: a systematic review and meta-analysis. Am J Epidemiol. 2008;168:237–49.
9. Abnet CC, Freedman ND, Hollenbeck AR, et al. A prospective study of BMI and risk of oesophageal and gastric adenocarcinoma. Eur J Cancer. 2008;44:465–71.
10. Lagergren J, Bergström R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340:825–31.
11. Kubo A, Corley DA. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomark Prev. 2006;15:872–8.
12. Ebi M, Shimura T, Yamada T, et al. Multicenter, prospective trial of white–light imaging alone versus white–light imaging followed by magnifying endoscopy with narrow-band imaging for the real-time imaging and diagnosis of invasion depth in superficial esophageal squamous cell carcinoma. Gastrointest Endosc. 2015;81:1355–61.
13. Kumagai Y, Inoue H, Nagai K, et al. Magnifying endoscopy, stereoscopic microscopy and the microvascular architecture of superficial esophageal carcinoma. Endoscopy. 2002;34:369–75.
14. Esaki M, Matsumoto T, Moriyama T, et al. Probe EUS for the diagnosis of invasion depth in superficial esophageal cancer: a comparison between a jelly–filled method and a water–filled balloon method. Gastrointest Endosc. 2006;63:389–95.
15. Katada C, Muto M, Manabe T, et al. Esophageal stenosis after endoscopic mucosal resection of superficial esophageal lesions. Gastrointest Endosc. 2003;57:165–9.
16. Ono S, Fujishiro M, Niimi K, et al. Predictors of postoperative stricture after esophageal endoscopic submucosal dissection for superficial squamous cell neoplasms. Endoscopy. 2009;41:661–5.
17. Shi Q, Ju H, Yao LQ, et al. Risk factors for postoperative stricture after endoscopic submucosal dissection for superficial esophageal carcinoma. Endoscopy. 2014;46:640–4.
18. Ezoe Y, Muto M, Horimatsu T, et al. Efficacy of preventive endoscopic balloon dilation for esophageal stricture after endoscopic resection. J Clin Gastroenterol. 2011;45:222–7.
19. Hashimoto S, Kobayashi M, Takeuchi M, et al. The efficacy of endoscopic triamcinolone injection for the prevention of esophageal stricture after endoscopic submucosal dissection. Gastrointest Endosc. 2011;74:1389–93.
20. Hanaoka N, Ishihara R, Takeuchi Y, et al. Intralesional steroid injection to prevent stricture after endoscopic submucosal dissection for esophageal cancer: a controlled prospective study. Endoscopy. 2012;44:1007–11.
21. Yamaguchi N, Isomoto H, Nakayama T, et al. Usefulness of oral prednisolone in the treatment of esophageal stricture after endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma. Gastrointest Endosc. 2011;73:1115–21.
22. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01).Radiat Therapy Oncology Group. JAMA. 1999;281:1623–7.
23. Wong RK, Malthaner RA, Zuraw L, Cancer Care Ontario Practice Guidelines Initiative Gastrointestinal Cancer Disease Site Group, et al. Combined modality radiotherapy and chemotherapy in nonsurgical management of localized carcinoma of the esophagus: a practice guideline. Int J Radiat Oncol Biol Phys. 2003;55:930–42.
24. Wong R, Malthaner R. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev. 2006;25:92.
25. Yamada K, Murakami M, Okamoto Y, et al. Treatment results of chemoradiotherapy for clinicalstage I (T1N0M0) esophageal carcinoma. Int J Rad Oncol Biol. Phys. 2006;64:1106–11.
26. Kato H, Sato A, Fukuda H, et al. A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study (JCOG9708). Jpn J Clin Oncol. 2009;39:638–43.
27. Kawashima M, Kagami Y, Toita T, et al. Prospective trial of radiotherapy for patients 80 years of age or older with squamous cell carcinoma of the thoracic esophagus. Int J Radiat Oncol Biol Phys. 2006;64:1112–21.
28. Shioyama Y, Nakamura K, Sasaki T, et al. Clinical results of radiation therapy for stage I esophageal cancer: a single institutional experience. Am J Clin Oncol. 2005;28:75–80.
29. Sasaki T, Nakamura K, Shioyama Y, et al. Treatment outcomes of radiotherapy for patients with stage I esophageal cancer: a single institute experience. Am J Clin Oncol. 2007;30:514–9.
30. Ishikawa H, Sakurai H, Tamaki Y, et al. Radiation therapy alone for stage I (UICC T1N0M0) squamous cell carcinoma of the esophagus: indications for surgery or combined chemoradiotherapy. J Gastroenterol Hepatol. 2006;21:1290–6.
31. Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68–74.
32. Bedenne L, Michel P, Bouché O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25:1160–8.
33. Chiu PW, Chan AC, Leung SF, et al. Multicenter prospective randomized trial comparing standard esophagectomy with chemoradiotherapy for treatment of squamous esophageal cancer: early results from the Chinese University Research Group for Esophageal Cancer (CURE). J Gastrointest Surg. 2005;9:794–802.
34. Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23:2310–7.
35. Kato K, Muro K, Minashi K, Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group (JCOG), et al. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Rad Onol Biol Phys. 2011;81:684–90.
36. Abrams JA, Ono DL, Strauss J, et al. Esophagectomy compared with chemoradiation for early stage esophageal cancer in the elderly. Cancer. 2009;115:4924–33.
37. Adams R, Morgan M, Mukherjee S, et al. A prospective comparison of multidisciplinary treatment of oesophageal cancer with curative intent in a UK cancer network. Eur J Surg Oncol. 2007;33:307–13.
38. Ariga H, Nemoto K, Miyazaki S, et al. Prospective comparison of surgery alone and chemoradiotherapy with selective surgery in resectable squamous cell carcinoma of the esophagus. Int J Rad Onol Biol Phys. 2009;75:348–56.
39. Chan R, Morrill S, Freeman D Jr, et al. Bi–modality (chemo-radiation) versus tri-modality (chemo-radiation followed by surgery) treatment for carcinoma of the esophagus. Dis Esophagus. 2001;14:202–7.
40. Hironaka S, Ohtsu A, Boku N, et al. Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3) N(any) M(0) squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. 2003;57:425–33.
41. Hsu FM, Lin CC, Lee JM, et al. Improved local control by surgery and paclitaxel–based chemoradiation for esophageal squamous cell carcinoma: results of a retrospective non-randomized study. J Surg Oncol. 2008;98:34–41.
42. Matsuda S, Tsubosa Y, Niihara M, et al. Comparison of transthoracic esophagectomy with definitive chemoradiotherapy as initial treatment for patients with esophageal squamous cell carcinoma who could tolerate transthoracic esophagectomy. Ann Surg Oncol. 2015;22:1866–73.
43. Nagata M, Yamamoto H, Takiguchi N, et al. Neoadjuvant chemoradiotherapy followed by esophagectomy versus definitive chemoradiotherapy in resectable stage II/III (T1–3N0, 1M0) esophageal squamous cell carcinoma. Esophagus. 2006;3:105–11.
44. Yamashita H, Nakagawa K, Yamada K, et al. A single institutional non–randomized retrospective comparison between definitive chemoradiotherapy and radical surgery in 82 Japanese patients with resectable esophageal squamous cell carcinoma. Dis Esophagus. 2008;21:430–6.
45. Nomura M, Kato K, Ando N, et al. Comparison between neoadjuvant chemotherapy followed by surgery (NAC–S) and definitive chemoradiotherapy (CRT) for overall survival in patients with clinical stage II/III esophageal squamous cell carcinoma (ESCC) (JCOG1406–A). Jpn J Clin Oncol. 2017;17:1–7 (epub ahead of print).
46. Tachimori Y, Kanamori N, Uemura N, et al. Salvage esophagectomy after high-dose chemoradiotherapy for esophageal squamous cell carcinoma. J Thorac Cardiovas Surg. 2009;137:49–54.
47. Hirao M, Ando N, Tsujinaka T, Japan Esophageal Oncology Group/Japan Clinical Oncology Group, et al. Influence of preoperative chemotherapy for advanced thoracic oesophageal squamous cell carcinoma on perioperative complications. Br J Surg. 2011;98:1735–41.
48. Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27:851–6.
49. Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335:462–7.
50. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluoracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB9781. J Clin Oncol. 2008;26:1086–92.
51. Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;19:305–13.
52. Lee JL, Park SI, Kim SB, et al. A single institional phase III trail of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol. 2004;15:947–54.
53. Burmeister BH, Smithers BM, Gebski V, et al. Trans-Tasman Radiation Oncology Group; Australasian Gastro-Intestinal Trials Group. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005;6:659–68.
54. Le Prise E, Etienne PL, Meunier B, et al. A randomised study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer. 1994;73:1779–84.
55. Apipop C, Puttisak P, Preecha N. A prospective study of combined therapy in esophageal cancer. Hepatogastroenterology. 1994;41:391–3.
56. Nygaard K, Hagen S, Hansen HS, et al. Pre–operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg. 1992;16:1104–9 (discussion 1110).
57. Lv J, Cao XF, Zhu B, et al. Long–term efficacy of perioperative chemoradiotherapy on esophageal squamous cell carcinoma. World J Gatroenterol. 2010;16:1649–54.
58. Bosset JFE, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous–cell cancer of the esophagus. N Engl J Med. 1997;337:161–7.
59. Natsugoe S, Okumura H, Matsumoto M, et al. Randomized controlled study on preoperative chemoradiotherapy followed by surgery alone for esophageal squamous cell cancer in a single institution. Dis Esophagus. 2006;19:468–72.
60. Mariette C, Dahan L, Mornex F, et al. Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol. 2014;32:2416–22.
61. Shapiro J, van Lanschot JJB, Hulshof MCCM, CROSS study group, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16:1090–8.
62. Sjoquist KM, Burmeister BH, Smithers BM, Australasian Gastro-Intestinal Trials Group, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12:681–92.
63. Kumagai K, Rouvelas I, Tsai JA, et al. Meta–analysis of postoperative morbidity and perioperative mortality in patients receiving neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal and gastro–oesophageal junctional cancers. Br J Surg. 2014;101:321–38.
64. Klevebro F, Johnsen G, Johnson E, et al. Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oespphageal junction: a randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation. Eur J Surg Oncol. 2015;41:920–6.
65. Nakamura K, Kato K, Igaki H, et al. Three-arm phase III trial comparing cisplatin plus 5-FU versus docetaxel, cisplatin plus 5-FU versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT Study). Jpn J Clin Oncol. 2013;43:752–5.
66. Ando N, Iizuka T, Ide H, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study—JCOG9204. J Clin Oncol. 2003;21:4592–6.
67. Zhao Y, Dai Z, Min W, et al. Perioperative versus preoperative chemotherapy with surgery in patients with resectable squamous cell carcinoma of esophagus: a Phase III randomized trial. J Thorac Oncol. 2015;10:1349–56.
68. Ardalan B, Spector SA, Livingstone AS, et al. Neoadjuvant, surgery and adjuvant chemotherapy without radiation for esophageal cancer. Jpn J Clin Oncol. 2007;37:590–6.
69. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.
70. Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715–21.
71. Ando N, Iizuka T, Kakegawa T, et al. A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: the Japan Clinical Oncology Group Study. J Thorac Cardiovasc Surg. 1997;114:205–9.
72. Pouliquen X, Levard H, Hay JM, et al. 5-Fluorouracil and cisplatin therapy after palliative surgical resection of squamous cell carcinoma of the esophagus. A multicenter randomized trial. French Associations for Surgical Research. Ann Surg. 1996;223:127–33.
73. Zhang SS, Yang H, Xie X, et al. Adjuvant chemotherapy versus surgery alone for esophageal squamous cell carcinoma: a meta–analysis of randomized controlled trials and nonrandomized studies. Dis Esophagus. 2014;27:574–84.
74. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94–05) phase III trial of combined–modality therapy for esophageal cancer: high-dose versus standard–dose radiation therapy. J Clin Oncol. 2002;20:1167–74.
75. Ohtsu A, Boku N, Muro K, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol. 1999;17:2915–21.
76. Slabber CF, Nel JS, Schoeman L, et al. A randomized study of radiotherapy alone versus radiotherapy plus 5-fluorouracil and platinum in patients with inoperable, locally advanced squamous cancer of the esophagus. Am J Clin Oncol. 1998;21:462–5.
77. Shinoda M, Ando N, Kato K, et al. Randomized study of low-dose versus standard–dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). Cancer Sci. 2015;106:407–12.
78. Ishida K, Ando N, Yamamoto S, et al. Phase II study of cisplatin and 5–fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group Trial (JCOG9516). Jpn J Clin Oncol. 2004;34:615–9.
79. Tsushima T, Mizusawa J, Sudo K, Japan Esophageal Oncology Group of Japan Clinical Oncology Group (JCOG), et al. Risk factors for esophageal fistula associated with chemoradiotherapy for locally advanced unresectable esophageal cancer: a supplementary analysis of JCOG0303. Medicine (Baltimore). 2016;95:e3699.
80. Higuchi K, Komori S, Tanabe S, et al. Kitasato Digestive Disease and Oncology Group. Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501–P2). Int J Radiat Oncol Biol Phys. 2014;89:872–9.
81. Tomblyn MB, Goldman BH, Thomas CR Jr, et al. SWOG GI Committee. Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase–II study of the SWOG (S0414). J Thorac Oncol. 2012;7:906–12.
82. Chiarion-Sileni V, Corti L, Ruol A, Innocente R, et al. Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer. Br J Cancer. 2007;96:432–8.
83. Sur RK, Levin CV, Donde B, et al. Prospective randomized trial of HDR brachytherapy as a sole modality in palliation of advanced esophageal carcinoma—an International Atomic Energy Agency study. Int J Radiat Oncol Biol Phys. 2002;53:127–33.
84. Sur R, Donde B, Falkson C, et al. Randomized prospective study comparing high-dose-rate intraluminal brachytherapy (HDRILBT) alone with HDRILBT and external beam radiotherapy in the palliation of advanced esophageal cancer. Brachytherapy. 2004;3:191–5.
85. de Manzoni G, Pedrazzani C, Pasini F, et al. Chemoradiotherapy followed by surgery for squamous cell carcinoma of the thoracic esophagus with clinical evidence of adjacent organ invasion. J Surg Oncol. 2007;95:261–6.
86. Ikeda K, Ishida K, Sato N, et al. Chemoradiotherapy followed by surgery for thoracic esophageal cancer potentially or actually involving adjacent organs. Dis Esophagus. 2001;14:197–201.
87. Dutton SJ, Ferry DR, Blazeby JM, et al. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. Lancet Oncol. 2014;15:894–904.
88. Iizuka T, Kakegawa T, Ide H, et al. Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol. 1992;22:172–6.
89. Hayashi K, Ando N, Watanabe H, et al. Phase II evaluation of protracted infusion of cisplatin and 5–fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). Jpn J Clin Oncol. 2001;31:419–23.
90. Bleiberg H, Conroy T, Paillot B, et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer. 1997;33:1216–20.
91. Lorenzen S, Schuster T, Porschen R, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2009;20:1667–73.
92. Kato K, Kei M, Nobutoshi A, et al. The Japan Esophageal Oncology Group of the Japan Clinical Oncology Group (JCOG): a phase II study of nedaplatin and 5–fluorouracil in metastatic squamous cell carcinoma of the esophagus: the Japan Clinical Oncology Group (JCOG) Trial (JCOG 9905–DI). Esophagus. 2014;11:183–8.
93. Kato K, Tahara M, Hironaka S, et al. A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer Chemother Pharmacol. 2011;67:1265–72.
94. Muro K, Hamaguchi T, Ohtsu A, et al. A phase II study of single–agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol. 2004;15:955–9.
95. Ikeda E, Kojima T, Kaneko K, et al. Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia. Jpn J Clin Oncol. 2011;41:964–72.
96. Penniment MG, Harvey JA, Wong R, Best Practice in Advanced Esophageal Cancer: a Report on Trans-Tasman Radiation Oncology Group TROG 03.01 and NCIC CTG ES, et al. 2 multinational phase 3 study in advanced esophageal cancer (OC) comparing quality of life (QOL) and palliation of dysphagia in patients treated with radiation therapy (RT) or chemoradiation therapy (CRT). Int J Radiat Oncol Biol Phys. 2014;90(Supplement):S3.
97. Bergquist H, Wenger U, Johnsson E, et al. Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial. Dis Esophagus. 2005;18:131–9.
98. Homs MY, Steyerberg EW, Eijkenboom WM, et al. Single–dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. Lancet. 2004;364:1497–504.